Coya Therapeutics Inc. (COYA)
NASDAQ: COYA
· Real-Time Price · USD
5.95
0.03 (0.51%)
At close: Jun 26, 2025, 11:36 AM
0.51% (1D)
| Bid | 5.85 |
| Market Cap | 99.51M |
| Revenue (ttm) | 3.69M |
| Net Income (ttm) | -17.14M |
| EPS (ttm) | -1.07 |
| PE Ratio (ttm) | -5.56 |
| Forward PE | -2.97 |
| Analyst | Buy |
| Ask | 6.03 |
| Volume | 41,506 |
| Avg. Volume (20D) | 57,479 |
| Open | 5.90 |
| Previous Close | 5.92 |
| Day's Range | 5.82 - 6.01 |
| 52-Week Range | 4.65 - 10.24 |
| Beta | 0.21 |
About COYA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol COYA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for COYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Coya Therapeutics Inc. is scheduled to release its earnings on Aug 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+7.2%
Coya Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
8 months ago
-27.67%
Coya Therapeutics shares are trading lower. The company announced results from the placebo-controlled Phase 2 clinical trial of LD IL-2 in patients with mild to moderate Alzheimer's Disease.
1 month ago · businesswire.com
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) fun...
2 months ago · seekingalpha.com
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data ReleasePositive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase 2...
